Skip to main
CELC

Celcuity (CELC) Stock Forecast & Price Target

Celcuity (CELC) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Celcuity Inc. has experienced a substantial stock price appreciation of approximately 608% year-to-date, significantly outperforming industry benchmarks. The company’s positive outlook is further supported by the recent increase in gedatolisib sales estimates to $70 million, $462 million, and $827 million for the years 2025, 2026, and 2027 respectively, indicating a stronger market position due to expedited regulatory reviews and anticipated early share gains. Additionally, the successful results from the VIKTORIA-1 trial, demonstrating improved safety in HR+/HER2- breast cancer patients, have led to a raised probability of product launch from 80% to 90%, underscoring the promising prospects for Celcuity's pipeline.

Bears say

The excerpts indicate that Celcuity is experiencing a cautious outlook due to several financial and operational factors. The company's estimated R&D spending shows a slight decline, while total GAAP operating expenses have not significantly decreased, raising concerns about the efficiency of capital allocation. Additionally, the potential for delays in FDA decisions regarding gedatolisib and competition from larger pharmaceutical companies could result in adverse pricing impacts and lower-than-expected revenues, leading to a reassessment of the current stock valuation.

Celcuity (CELC) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celcuity (CELC) Forecast

Analysts have given Celcuity (CELC) a Buy based on their latest research and market trends.

According to 9 analysts, Celcuity (CELC) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $109.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $109.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celcuity (CELC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.